Condition
Heart Failure With Preserved Ejection Fraction
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 238 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownExercise Cardiovascular Magnetic Resonance In Heart Failure With Preserved Ejection FractionNCT07401771 · 2026-11-01
RECRUITINGHS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection FractionNCT07123779 · 2026-09-01
RECRUITINGA Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)NCT07795814 · 2026-08-25
RECRUITINGA Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart DiseaseNCT07214376 · 2026-08-21
RECRUITINGIncretin Therapies in Obesity-related HFpEFNCT07554638 · 2026-08-07
RECRUITINGEXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)NCT07202000 · 2026-06-03
RECRUITINGBOOST: Blended Onsite and Offsite Structured Exercise Training and CoachingNCT07413198 · 2026-05-05
RECRUITINGA Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection FractionNCT07269717 · 2026-03-30
RECRUITINGA Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart FailureNCT07083011 · 2025-11-01
RECRUITINGA Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMDNCT07093528 · 2025-10-16
RECRUITINGAtrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillation (AF), Heart Failure and Preserved Ejection Fraction: Heart Rate Regularization Versus Medical Rate ControlNCT06833138 · 2025-09-10
RECRUITINGMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25
RECRUITINGSHort Of Pace - Heart Failure (SHOP-HF)NCT06992089 · 2025-06-17
RECRUITINGThe PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF)NCT06702501 · 2025-02-17
RECRUITINGMyocardial Mechanisms in Heart Failure With Preserved Ejection FractionNCT06517186 · 2024-11-08
RECRUITINGManganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection FractionNCT06652763 · 2024-10-10
RECRUITINGLeg Heat Therapy in Heart Failure With Preserved Ejection FractionNCT06388226 · 2024-08-15
RECRUITINGManaging Congestion in Heart Failure: A Mechanistic Study in Patients With HFpEFNCT06977477 · 2024-06-18
RECRUITINGFiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)NCT06337812 · 2024-04-01
RECRUITINGEMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal DiseaseNCT06249945 · 2024-03-05
RECRUITINGArterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEFNCT06208007 · 2024-02-23
RECRUITINGA Preliminary Study for INFORMEDNCT05585125 · 2024-02-07
RECRUITINGMyocardial Stiffness Evaluation in Patients With Heart Failure With Preserved Ejection FractionNCT06196086 · 2023-12-20
RECRUITINGExercise Capacity Improvement by Conduction System Pacing in heArt Failure patieNts Without Compelling CRT inDicationNCT06278844 · 2023-12-12
RECRUITINGModulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection FractionNCT06061549 · 2023-08-24
RECRUITINGPioglitazone on Heart Failure in Type-2 Diabetes Mellitus ParticipantsNCT05838287 · 2023-07-10
RECRUITINGTargeting Breathing Limitations to Improve Functional Outcomes in HFpEFNCT05723679 · 2023-07-01
RECRUITINGPBMC as Biomarkers of Diabetic CardiomyopathyNCT05651919 · 2023-05-23
RECRUITINGKetogenic Diet vs Mixed Diet in Patients With Heart FailureNCT06081543 · 2023-05-19
RECRUITINGCardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis TransitionNCT06409585 · 2023-05-01
RECRUITINGProvocative Tests for HFpEFNCT06309550 · 2023-03-10
RECRUITINGCAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection FractionNCT05508256 · 2023-03-01
RECRUITINGHeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment TargetsNCT05873634 · 2023-03-01
RECRUITINGPhysical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection FractionNCT05525663 · 2023-02-16
RECRUITINGExercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection FractionNCT05582044 · 2023-01-25
RECRUITINGThe Effect of Obesity and Weight Loss in Heart Failure With Preserved Ejection FractionNCT05878912 · 2023-01-20
RECRUITINGAssessment of CCM in HF With Higher Ejection FractionNCT05064709 · 2022-02-03
RECRUITINGSGLT2i and KNO3 in HFpEF - The SAK HFpEF TrialNCT05138575 · 2022-01-24
RECRUITINGBeta-blocker Discontinuation in Heart Failure With Preserved Ejection FractionNCT05174351 · 2021-12-20
RECRUITINGMatching Perfusion and Metabolic Activity in HFpEFNCT04913805 · 2021-10-11
RECRUITINGNovel Approaches for Improving Vascular Function in Veterans With HFpEFNCT06312748 · 2021-05-19
RECRUITINGSGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research PlanNCT05057806 · 2021-01-13
RECRUITINGThe Prognostic Role and Diagnostic Efficacy of Exercise Right Heart Catheterization With a Simultaneous Echocardiography in Patients With Dyspnea on ExertionNCT05490901 · 2020-03-17
RECRUITINGReal-Time Monitoring of Heart Failure Across the Yale New Haven Health SystemNCT04237701 · 2019-10-01
RECRUITINGPurinergic Signaling and the Postmenopausal HeartNCT06015776 · 2019-07-01
RECRUITINGSpironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection FractionNCT02901184 · 2017-11-23
RECRUITINGGLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF RegistryNCT07787936 · 2027-01-01
NOT_YET_RECRUITINGPulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection FractionNCT07331220 · 2026-12-30
NOT_YET_RECRUITINGCASTLE-HFpEF (Catheter Ablation for Atrial Fibrillation Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction)NCT07254455 · 2026-10-01
NOT_YET_RECRUITINGFinerenone and Cardiac Remodeling in HFpEFNCT07830940 · 2026-09-20
NOT_YET_RECRUITINGNeprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection FractionNCT06536309 · 2026-08-27
WITHDRAWNIV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron DeficiencyNCT07686692 · 2026-08-01
NOT_YET_RECRUITINGAI-based Echocardiographic Quantification in Heart FailureNCT07010952 · 2025-07-01
NOT_YET_RECRUITINGTransitions of Care Clinic (TOCC)NCT06937827 · 2025-06-26
TERMINATEDStaging Heart Failure With Preserved Ejection FractionNCT06931015 · 2025-04-20
NOT_YET_RECRUITINGStudy of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection FractionNCT06581159 · 2025-01-23
TERMINATEDSleep Extension to Improve Sleep Efficiency and QoL in HF With Preserved Ejection Fraction: the SLEEP-HF Pilot StudyNCT06567925 · 2025-01-21
COMPLETEDEmulation of the EMPEROR-Preserved Trial Using Healthcare Claims DataNCT07599293 · 2024-10-13
COMPLETEDChemoreflex Sensitivity in HFpEFNCT06309537 · 2024-10-01
NOT_YET_RECRUITINGFast Induced Remodeling in Heart Failure With Preserved Ejection FractionNCT05839730 · 2024-09-11
ACTIVE_NOT_RECRUITINGCommon interventions
PlaceboDRUG30PlaceboOTHER5DapagliflozinDRUG3EchocardiographyDIAGNOSTIC_TEST3Empagliflozin 10 MGDRUG3Ketone esterDIETARY_SUPPLEMENT3placebo drinkDIETARY_SUPPLEMENT3Sacubitril-ValsartanDRUG3ValsartanDRUG3Beta blockersDRUG2ColchicineDRUG2Dapagliflozin 10 MG [Farxiga]DRUG2EchocardiogramDIAGNOSTIC_TEST2ElectrocardiogramDIAGNOSTIC_TEST2Empagliflozin 25 MGDRUG2EnalaprilDRUG2Ferric derisomaltoseDRUG2JK07DRUG2MetforminDRUG2Placebo Oral TabletDRUG2sacubitril/valsartanDRUG2Transthoracic EchocardiographyDIAGNOSTIC_TEST2Usual CareBEHAVIORAL20.9% Sodium ChlorideDRUG12d speckle tracking echocardiographyDIAGNOSTIC_TEST1
Leading sponsors
Chongqing Medical University
8
Mayo Clinic
7
University of Leicester
5
University of Pennsylvania
5
Massachusetts General Hospital
4
Northwestern University
4
Samsung Medical Center
4
University of Texas Southwestern Medical Center
4
Wake Forest University Health Sciences
4
Assistance Publique - Hôpitaux de Paris
3
Brigham and Women's Hospital
3
Heart Center Leipzig - University Hospital
3
University of Michigan
3
Weill Medical College of Cornell University
3
35Pharma Inc
2
Trial status mix
COMPLETED84
UNKNOWN55
RECRUITING46
TERMINATED17
ACTIVE_NOT_RECRUITING14
NOT_YET_RECRUITING11
WITHDRAWN10
ENROLLING_BY_INVITATION1
Phase mix
NA68
PHASE238
PHASE426
PHASE316
PHASE19
EARLY_PHASE14
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.